Background： The domestic prevalence of chronic hepatitis B （CHB） in China is 7.18% in 2006, imposing great societal healthcare burdens. Nucleot（s）ide analogues （NUCs） anti-hepatitis B virus （HBV） therapies ar...Background： The domestic prevalence of chronic hepatitis B （CHB） in China is 7.18% in 2006, imposing great societal healthcare burdens. Nucleot（s）ide analogues （NUCs） anti-hepatitis B virus （HBV） therapies are widely applied despite the relatively low rate of seroconversion and high risk of drug-resistant mutation. More effective treatments for CHB deserve further explorations. Combined therapy of NUCs plus Chinese herbal medicine （CHM） is widely accepted in China, which is recognized as a prospective alternative approach. The study was primarily designed to confirm the hypothesis that Tiaogan-Yipi Granule （调肝益脾颗粒, TGYP） or Tiaogan-Jianpi-Jiedu Granule （调肝健脾解毒颗粒, TGJPJD） plus entecavir tablet （ETV） was superior over ETV monotherapy in enhancing HBeAg loss rate. Methods： The study was a nationwide, large-scale, multi-center, double-blind, randomized, placebo-controlled trial with a designed duration of 108 weeks. A total of 16 hospitals and 596 eligible Chinese HBeAg positive CHB patients were enrolled from November 2012 to September 2013 and randomly allocated into 2 groups in 1：1 ratio via central randomization system： experimental group （EG） and control group （CG）. Subjects in EG received CM formulae （TGYP or TGJPJD, 50 g per dose, twice daily） plus ETV tablet （or ETV placebo） 0.5 mg per day in the first 24 weeks （stage 1）, and CHM granule plus ETV tablet （0.5 mg per day） from week 25 to 108 （stage 2）. Subjects in CG received CHM Granule placebo plus E＇IV tablet （0.5 mg per day） for 108 weeks throughout the trial. The assessments of primary outcomes （HBV serum markers and HBV-DNA） were conducted by a third-party College of American Pathologists （CAP） qualified laboratory. Adverse effects were observed in the hospitals of recruitment. Discussion： The study was designed to compare the curative effect of CM plus E＇IV and ETV monotherapy in respect of HBeAg loss, which is recognized by the European Asso展开更多
目的评价水疗治疗类风湿性关节炎患者的疗效。方法检索Pubmed、Cochrane library、Embase、EBsco、Web of science、CNKI、Wanfang Data、VIP和SinoMed数据库,以类风湿性关节炎患者为研究对象,收集水疗治疗类风湿性关节炎患者的随机对...目的评价水疗治疗类风湿性关节炎患者的疗效。方法检索Pubmed、Cochrane library、Embase、EBsco、Web of science、CNKI、Wanfang Data、VIP和SinoMed数据库,以类风湿性关节炎患者为研究对象,收集水疗治疗类风湿性关节炎患者的随机对照试验(RCT)。检索时限设定为建库至2021年3月。两名研究人员按照纳入与排除标准独立筛选文献、提取资料和质量评价。采用Stata 15.0软件进行Meta分析。结果共纳入10个RCT,共计788例患者。Meta分析结果显示,水疗组的类风湿性关节炎患者临床总有效率高于非水疗组[RR=1.213,95%CI(1.119,1.315),P<0.001]。水疗组在疼痛评分、关节压痛数和关节肿胀数方面疗效均优于非水疗组[SMD=-0.241,95%CI(-0.458,-0.025),P=0.029;WMD=-3.464,95%CI(-5.756,-1.173),P=0.003;WMD=-1.976,95%CI(-3.654,-0.279),P=0.022]。结论水疗可以改善类风湿性关节炎患者的症状,缓解疼痛,减轻关节负担。展开更多
目的:评价温经通络中药治疗膝骨关节炎的有效性和安全性。方法:计算机检索中国知识资源总库(CNKI)、维普中文科技期刊全文数据库、万方数据学术论文总库及Pubmed、Web of science、Elsevier等数据库中关于温经通络中药对比其他药物治疗...目的:评价温经通络中药治疗膝骨关节炎的有效性和安全性。方法:计算机检索中国知识资源总库(CNKI)、维普中文科技期刊全文数据库、万方数据学术论文总库及Pubmed、Web of science、Elsevier等数据库中关于温经通络中药对比其他药物治疗膝骨关节炎的临床对照研究。对纳入研究的试验根据Jadad评分量表和Cochrane Handbook 5.1评估文献质量和偏倚风险,采用软件Revman 5.3.5进行数据分析。结果:共纳入22项临床研究、1651个病例,温经通络中药组852例,对照组799例。Meta分析表明:温经通络中药与对照组相比有更高的临床有效率和安全性,能更显著地降低WOAMC评分、VAS评分和中医证候评分。结论:温经通络中药可以有效改善KOA患者的临床症状,安全性较高,值得在临床推广应用。本次系统评价仍存在一些局限性,未来需要更多高质量的临床研究来进一步证实。展开更多
基金Supported by China National Science and Technology Major Projects 12th 5-year Plan(No.2012ZX10005004)
文摘Background： The domestic prevalence of chronic hepatitis B （CHB） in China is 7.18% in 2006, imposing great societal healthcare burdens. Nucleot（s）ide analogues （NUCs） anti-hepatitis B virus （HBV） therapies are widely applied despite the relatively low rate of seroconversion and high risk of drug-resistant mutation. More effective treatments for CHB deserve further explorations. Combined therapy of NUCs plus Chinese herbal medicine （CHM） is widely accepted in China, which is recognized as a prospective alternative approach. The study was primarily designed to confirm the hypothesis that Tiaogan-Yipi Granule （调肝益脾颗粒, TGYP） or Tiaogan-Jianpi-Jiedu Granule （调肝健脾解毒颗粒, TGJPJD） plus entecavir tablet （ETV） was superior over ETV monotherapy in enhancing HBeAg loss rate. Methods： The study was a nationwide, large-scale, multi-center, double-blind, randomized, placebo-controlled trial with a designed duration of 108 weeks. A total of 16 hospitals and 596 eligible Chinese HBeAg positive CHB patients were enrolled from November 2012 to September 2013 and randomly allocated into 2 groups in 1：1 ratio via central randomization system： experimental group （EG） and control group （CG）. Subjects in EG received CM formulae （TGYP or TGJPJD, 50 g per dose, twice daily） plus ETV tablet （or ETV placebo） 0.5 mg per day in the first 24 weeks （stage 1）, and CHM granule plus ETV tablet （0.5 mg per day） from week 25 to 108 （stage 2）. Subjects in CG received CHM Granule placebo plus E＇IV tablet （0.5 mg per day） for 108 weeks throughout the trial. The assessments of primary outcomes （HBV serum markers and HBV-DNA） were conducted by a third-party College of American Pathologists （CAP） qualified laboratory. Adverse effects were observed in the hospitals of recruitment. Discussion： The study was designed to compare the curative effect of CM plus E＇IV and ETV monotherapy in respect of HBeAg loss, which is recognized by the European Asso
